GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Beta

Science 37 Holdings (Science 37 Holdings) Beta : N/A (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-17), Science 37 Holdings's Beta is Not available.


Science 37 Holdings Beta Historical Data

The historical data trend for Science 37 Holdings's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science 37 Holdings Beta Chart

Science 37 Holdings Annual Data
Trend Jun20 Jun21 Dec22
Beta
- - -

Science 37 Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Science 37 Holdings's Beta

For the Health Information Services subindustry, Science 37 Holdings's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Science 37 Holdings's Beta Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Science 37 Holdings's Beta distribution charts can be found below:

* The bar in red indicates where Science 37 Holdings's Beta falls into.



Science 37 Holdings Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Science 37 Holdings  (NAS:SNCE) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Science 37 Holdings Beta Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Science 37 Holdings (Science 37 Holdings) Business Description

Traded in Other Exchanges
N/A
Address
800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709
Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.
Executives
Troy Bryenton officer: Chief Technology Officer 800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari officer: Chief Legal Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von director BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton officer: Chief Commercial Officer 800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman officer: Chief Delivery Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman director, officer: Chief Executive Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar officer: Chief Medical Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon officer: Chief Commercial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B. director PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek officer: Chief Financial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc. 10 percent owner 929 NORTH FRONT STREET, WILMINGTON NC 28401-3331